Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aumolertinib - Jiangsu Hansoh Pharmaceutical

Next Previous
Drug Profile

Aumolertinib - Jiangsu Hansoh Pharmaceutical

Alternative Names: Almonertinib; AMEILE; Amerol; Aumolertinib mesylate - Jiangsu Hansoh Pharmaceutical; EQ-143; HS-10206; HS-10296; HS-10296 mesylate

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Developer EQRx; Henan Cancer Hospital; Jiangsu Hansoh Pharmaceutical
  • Class Acrylamides; Amines; Antineoplastics; Cyclopropanes; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • No development reported Meningeal carcinomatosis; Solid tumours

Most Recent Events

  • 25 Apr 2025 Efficacy and adverse events data from phase III AENEAS2 trial in Non small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 25 Apr 2025 Efficacy and adverse events data from a phase III ARTS trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top